- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04264377
Towards Targeting the ORigin of the Inflammatory Cascade in Allergic Asthma (ORIENT)
Towards Targeting the ORigin of the Inflammatory Cascade in Allergic Asthma: Cross-talk Between Airway Epithelium and Immune Cells
Allergic asthma is a complex and heterogeneous disease caused by excessive responses to inhaled allergens. Current medication, including corticosteroids and bronchodilators, does not act on the origin of inflammation but rather combats symptoms, leaving many patients uncontrolled. Airway epithelium is critical for the initiation and progression of asthma pathology.
We will include a 52 subjects divided over two groups: ongoing asthma (26 patients) and non-asthmatic healthy controls (26 subjects) in a cross-sectional study. All subjects will be extensively clinically characterized including respiratory symptoms/questionnaires, in- and expiratory CT-scans, and parameters of large and small airway function and inflammation. In addition, blood and nasal epithelial brushes will be obtained to study the genetic and epigenetic mechanisms of asthma. Finally, bronchoscopy with bronchial biopsies and brushes will be performed under conscious sedation. Bronchial biopsies from both patient groups will be used for single cell transcriptional analysis.
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Maarten van den Berge, Dr
- Phone Number: +3150-3615260
- Email: m.van.den.berge@umcg.nl
Study Locations
-
-
-
Groningen, Netherlands, 9713GZ
- Recruiting
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion criteria for all subjects:
- Age between 18 and 45 years old.
- Smoking history ≤2 packyears.
Specific inclusion criteria for the two groups:
Group 1. Patients with ongoing asthma
- Age of onset of asthmatic symptoms: 0 - 18 years.
- Documented history of asthma diagnosed according to latest GINA guidelines, i.e. respiratory symptoms and either bronchodilator reversibility (improvement in FEV1 of more than 12% of baseline (and at least 200 mL) after inhalation of 800 µg salbutamol).
- Use of inhaled corticosteroids or either persistent symptoms of wheeze, cough, or dyspnea or regular use of β2 agonists at least once a week during the last 2 months.
- PC20 methacholine < 8 mg/ml.
Group 2. Non-asthmatic controls
- No history of asthma.
- No use of inhaled corticosteroids or β2-agonists for a period longer than 1 month.
- No symptoms of wheeze, nocturnal dyspnea, or bronchial hyperresponsiveness.
- PC20 methacholine > 8 mg/ml, FEV1/FVC > 70% and FEV1 > 80% predicted.
Exclusion Criteria:
- FEV1 <1.2 L,
- Subjects must be able to adhere to the study visit schedule and other protocol requirements.
- A subject is not eligible to enter and participate if he has not signed and dated a written informed consent form prior to participation in the study.
- A subjects is not eligible to enter and participate if he does not agree that we inform his general practitioner.
- Upper respiratory tract infection (e.g. colds), within 6 weeks.
- Serious acute infections (such as hepatitis, pneumonia or pyelonephritis) in the previous 3 months.
- Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
- Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
- Known recent substance abuse (drug or alcohol).
Females of childbearing potential without an efficient contraception unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH >40 mIU/mL or the use of one or more of the following acceptable methods of contraception:
- Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy).
- Hormonal contraception (implantable, patch, oral, injectable).
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository.
- Continuous abstinence.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy
26 healthy subjects
|
Bronchoscopy for retrieval of airway cells
|
Asthma
26 subjects with asthma
|
Bronchoscopy for retrieval of airway cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Single-cell transcriptomics bronchial epithelial cell (BEC)
Time Frame: december 2022
|
december 2022
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maarten van den Berge, Dr., UMCG
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201900308
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Bronchoscopy
-
Ankara Ataturk Sanatorium Training and Research...Yenimahalle Education and Research HospitalCompletedIntensive Care Unit | Tracheal StenosisTurkey
-
Tang-Du HospitalChanghai Hospital; The First Affiliated Hospital of Guangzhou Medical University and other collaboratorsTerminated
-
Jiayuan SunUnknown
-
Wake Forest University Health SciencesOhio State University; University of Mississippi Medical CenterCompletedBone Marrow TransplantationUnited States
-
Charite University, Berlin, GermanyUniversity of Luebeck; NeuroCure Clinical Research Center, Charite, Berlin; University... and other collaboratorsRecruiting
-
Centre Hospitalier Universitaire de NiceCompleted
-
University of VirginiaCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Instituto de Salud Carlos...UnknownBacterial Infection in COPDSpain
-
Dr Annelie F Behndig, MD PhDCompletedPulmonary Disease, Chronic ObstructiveSweden